Dendritic cells and cancer immunotherapy

Radford, Kristen J.; Tullett, Kirsteen M.; Lahoud, Mireille H.

doi:10.1016/j.coi.2014.01.005

Cited by 110 publications

(105 citation statements)

References 62 publications

Supporting

Mentioning

101

Contrasting

Unclassified

Order By: Relevance

“…Dendritic cells (DC) are commonly used as biologic therapy for cancer because of their physiologic roles in initiating and modulating the host immune response (1,2). In many cases, monocytes obtained from patients by apheresis have been used as a source of DCs (3,4).…”

Section: Introductionmentioning

confidence: 99%

Generation of Mouse Pluripotent Stem Cell–Derived Proliferating Myeloid Cells as an Unlimited Source of Functional Antigen-Presenting Cells

Zhang

Liu

Senju

et al. 2015

Cancer Immunology Research

View full text Add to dashboard Cite

The use of dendritic cells (DC) to prime tumor-associated antigen-specific T-cell responses provides a promising approach to cancer immunotherapy. Embryonic stem cells (ESC) and induced pluripotent stem cells (iPSC) can differentiate into functional DCs, thus providing an unlimited source of DCs. However, the previously established methods of generating practical volumes of DCs from pluripotent stem cells (PSC) require a large number of PSCs at the start of the differentiation culture. In this study, we generated mouse proliferating myeloid cells (pMC) as a source of antigen-presenting cells (APC) using lentivirus-mediated transduction of the c-Myc gene into mouse PSC-derived myeloid cells. The pMCs could propagate almost indefinitely in a cytokine-dependent manner, while retaining their potential to differentiate into functional APCs. After treatment with IL4 plus GM-CSF, the pMCs showed impaired proliferation and differentiated into immature DC-like cells (pMC-DC) expressing low levels of major histocompatibility complex (MHC)-I, MHC-II, CD40, CD80, and CD86. In addition, exposure to maturation stimuli induced the production of TNFα and IL12p70, and enhanced the expression of MHC-II, CD40, and CD86, which is thus suggestive of typical DC maturation. Similar to bone marrow–derived DCs, they stimulated a primary mixed lymphocyte reaction. Furthermore, the in vivo transfer of pMC-DCs pulsed with H-2Kb-restricted OVA257-264 peptide primed OVA-specific cytotoxic T cells and elicited protection in mice against challenge with OVA-expressing melanoma. Overall, myeloid cells exhibiting cytokine-dependent proliferation and DC-like differentiation may be used to address issues associated with the preparation of DCs. Cancer Immunol Res; 3(6); 668–77. ©2015 AACR.

show abstract

Section: Introductionmentioning

confidence: 99%

Generation of Mouse Pluripotent Stem Cell–Derived Proliferating Myeloid Cells as an Unlimited Source of Functional Antigen-Presenting Cells

Zhang

Liu

Senju

et al. 2015

Cancer Immunology Research

View full text Add to dashboard Cite

show abstract

“…24,25 Dendritic cells (DCs) as professional antigen (Ag)-presenting cells (APCs) are capable of directing Ag-specific immune responses; 26 therefore, the use of DCs has become a promising method for cancer immunotherapy. [27][28][29] The purpose of DC vaccination is to induce tumor-specific effector T cells with immunological memory in order to control tumor recurrence. 29,30 To improve the outcomes, DC vaccines need to be combined with other therapies that target immunosuppressive mechanisms by which tumor cells escape T-cell responses.…”

Section: Introductionmentioning

confidence: 99%

“…[27][28][29] The purpose of DC vaccination is to induce tumor-specific effector T cells with immunological memory in order to control tumor recurrence. 29,30 To improve the outcomes, DC vaccines need to be combined with other therapies that target immunosuppressive mechanisms by which tumor cells escape T-cell responses. 31,32 In this study, we targeted A2AR and CD73 in conjunction with DC therapy in a mouse breast tumor model.…”

Section: Introductionmentioning

confidence: 99%

Increased efficacy of a dendritic cell–based therapeutic cancer vaccine with adenosine receptor antagonist and CD73 inhibitor

et al. 2017

View full text Add to dashboard Cite

Dendritic cells are important in initiating immune responses; therefore, a range of dendritic cell-based approaches have been established to induce immune response against cancer cells. However, the presence of immunosuppressive mediators such as adenosine in the tumor microenvironment reduces the efficacy of dendritic cell-based cancer immunotherapy. In this study, we investigated whether blockade of the A2A adenosine receptor with a selective antagonist and a CD73 inhibitor may increase the efficacy of a dendritic cell-based cancer vaccine. According to the findings, this therapeutic combination reduced tumor growth, prolonged survival of tumor-bearing mice, and enhanced specific antitumor immune responses. Thus, we suggest that targeting cancer-derived adenosine improves the outcomes of dendritic cell-based cancer immunotherapy.

show abstract

“…This therapy is prescribed for prostate cancer patients, and has been found to prolong patients' life by 4 months. DC-targeting-based preventive and therapeutic vaccines are a personalized medication technique in which DCs are isolated from the blood of the patient and exposed to antigens and various other maturation stimuli before reinjecting them into the patient [62][63][64][65][66]. The challenges in these treatments are primarily due to medical and logistical complexities.…”

Section: Biomaterials For Immune Therapy Against Cancermentioning

confidence: 99%